Hypotension

Cardiovascular·MeSH: Hypotension

Prevalence

47000.0 / 100K

Incidence

3000.0 / 100K/yr

12 drugs in development·9 companies·2 clinical trials

Drug Pipeline by Phase

Approved(6)

Drug	Company
cefepime	Atara Biotherapeutics, Inc. (ATRA)
cefepime	Seagen Inc. (SGEN)
emerphed	NEXUS BIOPHARMA INC (NEXS)
GIAPREZA®	Innoviva, Inc. (INVA)
norepinephrine bi	Amneal Pharmaceuticals, Inc. (AMRX)
sodium nitroprusside	NEXUS BIOPHARMA INC (NEXS)

Phase 3(2)

Drug	Company
Acetazolamide-based medical therapy	Cidara Therapeutics, Inc. (CDTX)
ampreloxetine	Theravance Biopharma, Inc. (TBPH)

Phase 2(1)

Drug	Company
regn7544	REGENERON PHARMACEUTICALS, INC. (REGN)

Early Phase 1(1)

Drug	Company
Opioid-based anesthesia	Cidara Therapeutics, Inc. (CDTX)

Phase 4(2)

Drug	Company
0.9 %	GH Research PLC (GHRS)
adrenaline	GH Research PLC (GHRS)

BioSniper tracks 12 drugs in development for Hypotension across 9 companies.

There are 2 clinical trials targeting Hypotension tracked by BioSniper.

The estimated prevalence of Hypotension is approximately 47000.0 per 100,000 population.

Full trial data, competitive analysis, and AI-powered pipeline tracking.